Literature DB >> 12958358

Constitutive display of cryptic translation products by MHC class I molecules.

Susan R Schwab1, Katy C Li, Chulho Kang, Nilabh Shastri.   

Abstract

Major histocompatibility complex (MHC) class I molecules display tens of thousands of peptides on the cell surface, derived from virtually all endogenous proteins, for inspection by cytotoxic T cells (CTLs). We show that, in normal mouse cells, MHC I molecules present a peptide encoded in the 3' "untranslated" region. Despite its rarity, the peptide elicits CTL responses and induces self-tolerance, establishing that immune surveillance extends well beyond conventional polypeptides. Furthermore, translation of this cryptic peptide occurs by a previously unknown mechanism that decodes the CUG initiation codon as leucine rather than the canonical methionine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12958358     DOI: 10.1126/science.1085650

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  41 in total

Review 1.  DRiPs solidify: progress in understanding endogenous MHC class I antigen processing.

Authors:  Jonathan W Yewdell
Journal:  Trends Immunol       Date:  2011-09-29       Impact factor: 16.687

2.  Rli1/ABCE1 Recycles Terminating Ribosomes and Controls Translation Reinitiation in 3'UTRs In Vivo.

Authors:  David J Young; Nicholas R Guydosh; Fan Zhang; Alan G Hinnebusch; Rachel Green
Journal:  Cell       Date:  2015-08-13       Impact factor: 41.582

3.  Impact of regulated secretion on antiparasitic CD8 T cell responses.

Authors:  Harshita Satija Grover; H Hamlet Chu; Felice D Kelly; Soo Jung Yang; Michael L Reese; Nicolas Blanchard; Federico Gonzalez; Shiao Wei Chan; John C Boothroyd; Nilabh Shastri; Ellen A Robey
Journal:  Cell Rep       Date:  2014-05-22       Impact factor: 9.423

4.  Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translation.

Authors:  Sebastien Apcher; Chrysoula Daskalogianni; Fabrice Lejeune; Bénédicte Manoury; Gabriela Imhoos; Lea Heslop; Robin Fåhraeus
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-27       Impact factor: 11.205

Review 5.  mRNA-based therapeutics--developing a new class of drugs.

Authors:  Ugur Sahin; Katalin Karikó; Özlem Türeci
Journal:  Nat Rev Drug Discov       Date:  2014-09-19       Impact factor: 84.694

Review 6.  Exploiting non-canonical translation to identify new targets for T cell-based cancer immunotherapy.

Authors:  Céline M Laumont; Claude Perreault
Journal:  Cell Mol Life Sci       Date:  2017-08-19       Impact factor: 9.261

7.  Physical and biochemical properties of mammalian DNase X proteins: non-AUG translation initiation of porcine and bovine mRNAs for DNase X.

Authors:  Daisuke Shiokawa; Yukari Shika; Kazuki Saito; Kosuke Yamazaki; Sei-ichi Tanuma
Journal:  Biochem J       Date:  2005-12-15       Impact factor: 3.857

8.  Epstein Barr virus-encoded EBNA1 interference with MHC class I antigen presentation reveals a close correlation between mRNA translation initiation and antigen presentation.

Authors:  Sebastien Apcher; Chrysoula Daskalogianni; Benedicte Manoury; Robin Fåhraeus
Journal:  PLoS Pathog       Date:  2010-10-14       Impact factor: 6.823

9.  Robust, vaccine-induced CD8(+) T lymphocyte response against an out-of-frame epitope.

Authors:  Nicholas J Maness; Nancy A Wilson; Jason S Reed; Shari M Piaskowski; Jonah B Sacha; Andrew D Walsh; Elizabeth Thoryk; Gwendolyn J Heidecker; Michael P Citron; Xiaoping Liang; Andrew J Bett; Danilo R Casimiro; David I Watkins
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

10.  CD8 T cell response and evolutionary pressure to HIV-1 cryptic epitopes derived from antisense transcription.

Authors:  Anju Bansal; Jonathan Carlson; Jiyu Yan; Olusimidele T Akinsiku; Malinda Schaefer; Steffanie Sabbaj; Anne Bet; David N Levy; Sonya Heath; Jianming Tang; Richard A Kaslow; Bruce D Walker; Thumbi Ndung'u; Philip J Goulder; David Heckerman; Eric Hunter; Paul A Goepfert
Journal:  J Exp Med       Date:  2010-01-11       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.